期刊文献+

人凝血因子Ⅷ制备工艺的优化 被引量:4

Preparation optimization of human coagulation factor Ⅷ
原文传递
导出
摘要 目的优化人凝血因子Ⅷ(FⅧ)原液制备工艺,提高FⅧ收得率及纯度。方法采用正交设计优化冷沉淀溶解工艺参数;探讨不同p H对冷沉淀溶解液酸性沉淀的影响,优化得到最佳酸性沉淀条件;通过对离子交换层析工艺的研究,得到离子交换层析的最佳上样流速及柱载量。结果冷沉淀溶解的最佳溶解工艺条件是溶解倍数为4倍、溶解温度为10℃、溶解时间为2 h;溶解液最佳酸性沉淀p H为7.2;离子交换层析的最佳上样流速为1.2 cm·min-1,每毫升凝胶对凝血因子Ⅷ的载量为80.1 IU·m L-1。结论通过对FⅧ原液制备工艺的优化,FⅧ收得率提高了约13%,比活性约提高了30 IU·mg-1。 Objective To improve the recovery rate and purity of human coagulation factor Ⅷ( F Ⅷ) by optimizing its preparation process. Methods Orthogonal design was used to optimize the parameter of cryoprecipitate dissolving process, to get the best acid precipitation conditions by exploring the effect on the acid precipitates of cryoprecipitate dissolving reagent by different p H values, and to get the best flow rate and column loads of ionexchange chromatography by studying the ion-exchange column chromatograph process. Results The best parameter of cryoprecipitate was that the dissolve ratio was 4, the dissolve temperature was 10 ℃, the dissolve time was 2 h, the p H of the best precipitates was 7.2, the best sample flow rate of ion-exchange column chromatography was 1.2 cm·min^- 1, and the column loads was 80.1 IU·m L^- 1 F Ⅷ gel. Conclusion By optimizing the preparation, the recovery of F Ⅷ has increased about 13%, and the specific activity has increased about 30 IU·mg^- 1.
出处 《中南药学》 CAS 2015年第2期141-143,共3页 Central South Pharmacy
关键词 人凝血因子Ⅷ 冷沉淀 离子交换 层析 human coagulation factor Ⅷ cryoprecipitate ionexchange chromatograph
  • 相关文献

参考文献9

二级参考文献60

共引文献64

同被引文献39

  • 1Woodhams B, Girardot O, Blanco M J, et al. Stability of coagula- tion proteins in frozen plasma [ J ]. Blood Coagul Fibrinolysis, 2001,12 (4) :229-236.
  • 2Franchini M, Mannueei PM. Past, present and future of hemo- philia: a narrative review [ J]. Orphanet J Rare Dis, 2012,7:24.
  • 3Mannueci PM. Back to the future : a recent history of haemophilia treatment [ J ]. Haemophilia ,2008,14 ( Suppl 3 ) : 10-18.
  • 4孙艳萍.冷沉淀的制备方法及临床输注[J].中国健康月刊,2011,30(7):309-310.
  • 5Mori F, Nardini I, Rossi P, et al. Progress in large-scale purifi- cation of factor Ⅷ/von Willebrand factor concentrates using ion- exchange chromatography[ J]. Vox Sang,2008,95 (4) :298-307.
  • 6郑炎,贾玉华,杨晓敏,等.二次病毒灭活冻干人凝血因子Ⅷ的研制[G]//中华医学会第八次全国血液学学术会议论文汇编.2004.
  • 7Burnouf T, Burnouf-Radosevich M, Huart JJ,et al. A highly pu- rified factor Ⅷ: c concentrate prepared from cryoprecipitate by ion-exchange chromatography[J]. Vox Sang,1991,60( 1 ) :8-15.
  • 8Cheng E, Jinzenji D, Paula A, et al. Purification of coagulation factor Ⅷ using chromatographic methods. Direct chromatogra- phy of plasma in anion exchange resins [ J ]. Biotechnol Lett, 2010, 32(9) :1207-1214.
  • 9D'Amici GM1 , Blasi B, D'Alessandro A,et al. Plasma-derived clotting factor Ⅷ:Heterogeneity evaluation in the quest for po- tential inhibitory-antibody stimulating factors [ J ]. Electrophore- sis ,2011, 32 ( 21 ) :2941-2950.
  • 10Morfini M, Coppola A, Franchini M, et al. Clinical use of factor Ⅷ and factor Ⅸ concentrates [ J ] Blood Transfus, 2013, 11 ( Suppl 4 ) : s55-63.

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部